根据动脉粥样硬化存在情况评估秋水仙碱用于卒中二级预防
在中位33.6个月随访中,动脉粥样硬化组接受秋水仙碱者主要不良心血管事件(MACE)数值上较少但未达统计学显著(HR 0.83,95%CI 0.64-1.07),非动脉粥样硬化组无差异(HR 0.94,95%CI 0.64-1.39;交互P=0.60)。预设的符合方案分析中,动脉粥样硬化组MACE风险显著降低(HR 0.76,95%CI 0.58-0.99)。
要点
- 动脉粥样硬化组秋水仙碱治疗MACE数值减少但意向性分析未显著。
- 符合方案分析中动脉粥样硬化组MACE风险显著降低(HR 0.76)。
- 非动脉粥样硬化组未见获益,交互作用不显著。
核心结论
- 意向性治疗和符合方案分析中,秋水仙碱与动脉粥样硬化对MACE的交互作用均不显著。
- 动脉粥样硬化患者接受秋水仙碱后MACE事件数值上更少,符合方案分析中获益显著。
- 数据提示未来抗炎治疗试验应将动脉粥样硬化存在作为入选标准。
研究设计与样本
- CONVINCE试验的事后分析,随机、开放标签、盲法终点评估。
- 比较秋水仙碱0.5 mg联合常规治疗与常规治疗。
- 主要结局为MACE,中位随访33.6个月。
主要发现
- 随访期间共发生338例MACE事件。
- 动脉粥样硬化组:秋水仙碱组MACE 105例(11.1%),发生率3.88/100人年(95%CI 3.21-4.70);常规治疗组132例(14.2%),发生率4.83/100人年(95%CI 4.07-5.73);HR 0.83(95%CI 0.64-1.07)。
- 非动脉粥样硬化组:HR 0.94(95%CI 0.64-1.39);交互作用P=0.60。
- 动脉粥样硬化组复发缺血性卒中:秋水仙碱组HR 0.76(95%CI 0.56-1.05);非动脉粥样硬化组HR 0.92(95%CI 0.60-1.42);交互作用P=0.48。
- 符合方案分析:动脉粥样硬化组秋水仙碱降低MACE风险HR 0.76(95%CI 0.58-0.99);非动脉粥样硬化组HR 0.95(95%CI 0.63-1.42);交互作用P=0.37。
关键数值与推荐
- 动脉粥样硬化定义:颈颅/主动脉斑块、冠心病、外周动脉疾病或颈动脉血运重建。
- 主要结局MACE;意向性治疗分析调整年龄、 qualifying event、事件至随机化时间及冠心病。
临床怎么用
- 对于非心源性卒中合并动脉粥样硬化的患者,秋水仙碱0.5 mg联合常规治疗可能降低MACE风险,但获益主要体现在符合方案分析中。
- 非动脉粥样硬化患者未观察到获益,不推荐常规使用秋水仙碱进行二级预防。
- 未来抗炎治疗试验可考虑将动脉粥样硬化存在作为入选标准。
局限性
- 本研究为事后分析,非预设主要分析,结果需谨慎解读。
- 意向性治疗分析中动脉粥样硬化组MACE减少未达统计学显著。
- 开放标签设计可能影响行为因素,尽管终点采用盲法评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-inflammatory therapies reduce the risk of major adverse cardiovascular events (MACEs) in coronary disease, but efficacy has not been shown after stroke. It is uncertain if patients with atherosclerosis are more likely to benefit from anti-inflammatory prevention. METHODS: We performed a post hoc analysis of the CONVINCE trial (randomized, open-label, blinded-end point assessed; Colchicine for Prevention of Vascular Inflammation in Non-Cardioembolic Stroke), comparing colchicine 0.5 mg plus usual care versus usual care. We performed a subgroup analysis in patients stratified according to the presence/absence of atherosclerosis (defined as cervico-cranial/aortic artery plaque, coronary disease, peripheral arterial disease, and carotid revascularization). The primary outcome was MACE. Analyses were adjusted for age, qualifying event, time from event to randomization, and coronary disease. RESULTS: Three thousand one hundred forty-four participants were included. There were 338 MACE events during follow-up (median, 33.6 months). On intention-to-treat analysis, there were numerically fewer MACE events in the atherosclerosis group assigned to colchicine (105 [11.1%], 3.88 [95% CI, 3.21-4.70] per 100 person-years) versus usual care (132 [14.2%], 4.83 [4.07-5.73] per 100 person-years), which was not statistically significant (hazard ratio [HR], 0.83 [95% CI, 0.64-1.07]). There was no difference in the rate of the primary outcome according to treatment allocation in the nonatherosclerosis subgroup (HR, 0.94 [95% CI, 0.64-1.39]; Pinteraction=0.60). There was a nonsignificant reduced risk of recurrent ischemic stroke in the colchicine arm (HR, 0.76 [95% CI, 0.56-1.05]) in the atherosclerosis group, but no difference in events was observed in the nonatherosclerotic group (HR, 0.92 [95% CI, 0.60-1.42]; Pinteraction=0.48). In the prespecified on-treatment analysis, colchicine reduced the risk of MACE in patients with atherosclerosis (HR, 0.76 [95% CI, 0.58-0.99]) but not without (HR, 0.95 [95% CI, 0.63-1.42]; Pinteraction=0.37). CONCLUSIONS: There were no significant between-group interactions for colchicine and atherosclerosis for MACE in intention-to-treat or on-treatment populations. However, outcome events were numerically fewer in patients with atherosclerosis assigned to colchicine, and significant benefit was observed in the on-treatment analysis in this group. Data suggest that the presence of atherosclerosis should be an inclusion criterion in future anti-inflammatory therapy trials. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02898610.
引用
- McCabe JJ, Lemmens R, Purroy F, et al. Colchicine for Secondary Prevention After Stroke According to the Presence of Atherosclerosis. Stroke. 2026. PMID: 42619594. doi:10.1161/STROKEAHA.126.056561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。